证券代码：300759 证券简称：康龙化成 公告编号：2025-064 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持计划告知函》。信中康成持有公司股份 223,488,310 股（约占公司总股本的 12.57%），计划自本公告披露之日起 15 个交 易日后（2025 年 12 月 8 日）的 3 个月内以集中竞价、大宗交易等深圳证券交易 所认可的合法方式减持公司股份不超过 8,890,977 股（占公司总股本的 0.50%）； 信中龙成持有公司股份 28, ...

智通财经APP获悉，香港联交所最新资料显示，11月12日，Norges Bank增持康龙化成(03759)70.02万 股，每股作价23.8072港元，总金额约为1666.98万港元。增持后最新持股数目约为1827.04万股，最新持 股比例为6.21%。 ...

Investment Rating - The report maintains an "Accumulate" rating for the company [6]. Core Views - The company's performance in Q3 2025 met market expectations, with a significant acceleration in new orders. The revenue for Q1-Q3 2025 reached 10.086 billion yuan, a year-on-year increase of 14.38%, while the net profit attributable to shareholders was 1.141 billion yuan, a decrease of 19.76% year-on-year [1][2]. - The company expects a revenue growth guidance of 12% to 16% for 2025, supported by a strong order growth trend and ongoing cost reduction efforts [2][4]. Summary by Sections Financial Performance - In Q3 2025, the company achieved a revenue of 3.645 billion yuan, a year-on-year increase of 13.4%, and an adjusted profit of 471 million yuan, up 12.9% year-on-year. The new orders for Q1-Q3 2025 grew by over 13% year-on-year, showing an acceleration compared to the 10% growth in H1 2025 [2][3]. - The laboratory services segment generated 2.11 billion yuan in revenue in Q3 2025, growing 14.3% year-on-year, while the CMC business reported 900 million yuan, up 12.7% year-on-year [3]. Client Contributions - The top 20 global pharmaceutical clients contributed 616 million yuan in revenue in Q3 2025, reflecting a year-on-year growth of 22.19%, indicating strong performance resilience [3]. Future Outlook - The company is expected to benefit from a global economic recovery, with adjusted revenue forecasts for 2025-2027 slightly modified to 13.995 billion yuan, 16.183 billion yuan, and 18.877 billion yuan respectively. The earnings per share (EPS) estimates were adjusted to 0.88 yuan, 1.10 yuan, and 1.38 yuan for the same period [4][10].

Core Insights - The company maintains a "buy" rating with an upward revision of the annual performance guidance based on strong revenue growth and new order trends [1][3] Financial Performance - For Q1-Q3 2025, the company reported revenue of 10.086 billion yuan, a year-on-year increase of 14.38%, and an adjusted net profit of 1.227 billion yuan, up 10.76% year-on-year [1] - The gross margin stood at 34.22%, reflecting a slight increase of 0.35 percentage points year-on-year, while the adjusted net profit margin was 12.16%, down 0.40 percentage points year-on-year [1] - In Q3 alone, revenue reached 3.645 billion yuan, a 13.44% increase year-on-year, with an adjusted net profit of 471 million yuan, up 12.88% year-on-year [1] Segment Performance - Laboratory services generated revenue of 6.004 billion yuan in Q1-Q3 2025, a 15.04% increase year-on-year, with a gross margin of 45.13% [2] - The small molecule CDMO segment reported revenue of 2.293 billion yuan, up 15.99% year-on-year, with a gross margin of 32.10% [2] - Clinical research revenue was 1.440 billion yuan, a 10.26% increase year-on-year, but with a lower gross margin of 11.79% [2] - The large molecule and cell & gene therapy segment saw revenue of 336 million yuan, an 8.13% increase year-on-year, but with a negative gross margin of -49.15% [2] Order Trends - New orders for Q1-Q3 2025 increased by over 13% year-on-year, with laboratory services and CMC new orders growing by over 12% and approximately 20%, respectively [3] - The company has revised its full-year revenue guidance upward to a growth range of 12%-16% based on the new order trends [3] Catalysts - Improved investment and financing conditions, along with better-than-expected development in backend operations and enhanced operational efficiency, are seen as key catalysts for future growth [4]

Core Insights - The China Securities Index Co., Ltd. will officially launch the China Securities Innovation Drug Index and the China Securities Medical Device Index on November 7, providing richer investment targets for the market [1] Group 1: Innovation Drug Index - The China Securities Innovation Drug Index selects listed companies involved in innovative drug research and development, as well as those providing drug research, development, and production services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - A total of 50 constituent stocks have been included in the index, such as BeiGene, Boli Tianheng, Kanglong Chemical, and Zhifei Biological [4] - The innovative drug sector has attracted significant investor attention this year, with China's innovative drug pipeline and clinical trial projects ranking among the top globally [4] Group 2: Medical Device Index - The China Securities Medical Device Index selects listed companies that provide medical devices, consumables, and in vitro diagnostic products and services from the Sci-Tech Innovation Board and the Growth Enterprise Market [4] - 50 constituent stocks have been included in this index, including Mindray Medical, United Imaging, New Industry, and Aimeike [4] - The domestic medical device industry is experiencing rapid development, with a positive outlook on innovation-driven import substitution and global expansion [5]

Core Insights - The company reported a revenue of 10.086 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 14.4%, while the net profit attributable to shareholders decreased by 19.8% to 1.141 billion yuan [1] - The company raised its revenue growth target for 2025 to 12%-16% from the previous 10%-15%, indicating confidence in performance growth [1] Financial Performance - In Q3 2025, the company achieved a revenue of 3.645 billion yuan, a year-on-year increase of 13.4% and a quarter-on-quarter increase of 9.1%, marking a recent high for quarterly revenue [1] - The adjusted net profit margin for Q3 2025 was 10.89%, the best level since Q1 2024, reflecting improved operational efficiency as revenue scales up [1] Business Segment Analysis - The laboratory services segment generated revenue of 6.004 billion yuan in the first three quarters of 2025, with a gross margin of 45.1%, an increase of 0.3 percentage points year-on-year [2] - The CMC segment reported revenue of 2.293 billion yuan, with a gross margin of 32.1%, up 1.3 percentage points year-on-year, and is expected to see further improvements in Q4 2025 [2] Profit Forecast and Valuation - Revenue projections for 2025 to 2027 are set at 14.053 billion yuan, 16.034 billion yuan, and 18.090 billion yuan, with year-on-year growth rates of 14.5%, 14.1%, and 12.8% respectively [3] - Net profit forecasts for the same period are 1.669 billion yuan, 2.140 billion yuan, and 2.565 billion yuan, with growth rates of -6.9%, +28.2%, and +19.9% respectively [3]

Investment Rating - The investment rating for the company is "Buy" [1][3] Core Insights - The company has raised its revenue guidance for 2025, reflecting confidence in growth, with a target increase of 12%-16% compared to the previous 10%-15% [7] - The company's operating quality continues to improve, with significant growth in core business segments and a notable increase in new orders [7] - The financial forecasts for 2025 to 2027 indicate a steady revenue growth trajectory, with expected revenues of 140.53 billion yuan, 160.34 billion yuan, and 180.90 billion yuan respectively [4][7] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 100.86 billion yuan, a year-on-year increase of 14.4%, while the net profit attributable to shareholders was 11.41 billion yuan, down 19.8% [7] - The company reported a significant improvement in quarterly performance, with Q3 2025 revenue reaching 36.45 billion yuan, a 13.4% year-on-year increase and a 9.1% quarter-on-quarter increase [7] Business Segments - The laboratory services segment generated revenue of 60.04 billion yuan in the first three quarters of 2025, with a gross margin of 45.1%, reflecting a 0.3 percentage point increase year-on-year [7] - The CMC business segment reported revenue of 22.93 billion yuan, with a gross margin of 32.1%, up 1.3 percentage points year-on-year, indicating potential for further improvement [7] Profitability Forecast - The projected net profit for 2025 is 16.69 billion yuan, with a year-on-year growth rate of -6.9%, followed by a recovery in 2026 and 2027 with growth rates of 28.2% and 19.9% respectively [4][7] - The earnings per share (EPS) is expected to be 0.94 yuan in 2025, increasing to 1.20 yuan in 2026 and 1.44 yuan in 2027 [4][7]

Core Viewpoint - 康龙化成 is experiencing a slight increase in stock price and has a significant market capitalization, benefiting from various industry trends including digital transformation and AI integration in clinical services [1][2]. Company Overview - 康龙化成 (Beijing) New Drug Technology Co., Ltd. specializes in integrated drug research, development, and production services, covering the entire process from drug discovery to development [2][7]. - The company's main revenue sources include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and other services [7]. Financial Performance - For the period from January to September 2025, 康龙化成 achieved a revenue of 10.086 billion yuan, representing a year-on-year growth of 14.38%, while the net profit attributable to shareholders decreased by 19.76% to 1.141 billion yuan [8]. - The company has distributed a total of 1.794 billion yuan in dividends since its A-share listing, with 1.007 billion yuan distributed over the past three years [9]. Market Position and Trends - 康龙化成 is positioned as a leader in the CRO (Contract Research Organization) sector, particularly in small molecule drug research services, and ranks second in drug discovery in China [2][3]. - The company is benefiting from the depreciation of the RMB, with overseas revenue accounting for 84.95% of total revenue [3]. Digital Transformation and AI Integration - 康龙化成 has made significant progress in digital and intelligent construction within its clinical services, establishing a "Digital Innovation Technology Department" to enhance efficiency through automation and machine learning [3]. - The acquisition of Shanghai Jiying is expected to further promote the company's digital transformation in clinical services, although it may face integration and management challenges [2][3].

Group 1 - Norges Bank increased its stake in 康龙化成 (03759.HK) by purchasing 518,200 shares at an average price of HKD 25.7617 per share, amounting to approximately HKD 13.35 million [1] - Following the acquisition, Norges Bank's total shareholding rose to 14,730,424 shares, increasing its ownership percentage from 4.83% to 5.01% [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | ...